Effectiveness and mechanisms of sodium-dependent glucose transporter 2 inhibitors in type 2 diabetes and heart failure patients

doi:10.4330/wjc.v16.i10.611

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 10

This Article

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (2801)

All Articles published online

The chart showing PDF series, HTML series.

Item

Count

PDF

119

HTML

1276

Sum=1395

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

205

Download

532

Sum=737

Publishing Process of This Article

Item

Count

Browse

Download

453

Sum=547

Oct 26, 2024 (publication date) through Feb 28, 2026

Times Cited of This Article

Times Cited (1)

Journal Information of This Article

Publication Name

World Journal of Cardiology

ISSN

1949-8462

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Letter to the Editor

World J Cardiol. Oct 26, 2024; 16(10): 611-615
Published online Oct 26, 2024. doi: 10.4330/wjc.v16.i10.611

Effectiveness and mechanisms of sodium-dependent glucose transporter 2 inhibitors in type 2 diabetes and heart failure patients

Yan-Xi Zhang, Hai-Sheng Hu, Bao-Qing Sun

Yan-Xi Zhang, Hai-Sheng Hu, Bao-Qing Sun, Department of Clinical Laboratory, The First Affiliated Hospital of Guangzhou Medical University, State Key Laboratory of Respiratory Disease, National Center for Respiratory Medicine, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, Guangzhou 510120, Guangdong Province, China

Co-first authors: Yan-Xi Zhang and Hai-Sheng Hu.

Author contributions: Zhang YX and Hu HS contributed equally to this work; Sun BQ designed the overall concept and outline of the manuscript; Hu HS contributed to the discussion and design of the manuscript; Zhang YX contributed to the writing and editing of the manuscript and illustrations; and all authors have read and approved the final manuscript.

Conflict-of-interest statement: The authors have nothing to disclose.

Corresponding author: Bao-Qing Sun, PhD, Professor, Department of Clinical Laboratory, The First Affiliated Hospital of Guangzhou Medical University, State Key Laboratory of Respiratory Disease, National Center for Respiratory Medicine, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, No. 28 Qiaozhong Middle Road, Guangzhou 510120, Guangdong Province, China. sunbaoqing@vip.163.com

Received: August 16, 2024
Revised: September 29, 2024
Accepted: October 11, 2024
Published online: October 26, 2024
Processing time: 62 Days and 3.1 Hours

Abstract

We comment on an article by Grubić Rotkvić et al published in the recent issue of the World Journal of Cardiology. We specifically focused on possible factors affecting the therapeutic effectiveness of sodium-dependent glucose transporter inhibitors (SGLT2i) in patients with type 2 diabetes mellitus (T2DM) and their impact on comorbidities. SGLT2i inhibits SGLT2 in the proximal tubules of the kidneys, lowering blood glucose levels by inhibiting glucose reabsorption by the kidneys and causing excess glucose to be excreted in the urine. Previous studies have demonstrated a role of SGLT2i in cardiovascular function in patients with diabetes who take metformin but still have poor glycemic control. In addition, SGLT2i has been shown to be effective in anti-apoptosis, weight loss, and cardiovascular protection. Accordingly, it is feasible to treat patients with T2DM with cardiovascular or renal diseases using SGLT2i.

Keywords: Sodium-dependent glucose transporter inhibitors; Type 2 diabetes mellitus; Heart failure; Treatment; Cardiovascular disease

Core Tip: Studies have revealed that type 2 diabetes mellitus (T2DM) patients often suffer from multiple comorbidities that can be effectively treated with sodium-dependent glucose transporter inhibitors (SGLT2i), which has been linked to their anti-apoptotic properties, promotion of weight loss, and cardiovascular protection. Correctly avoiding the risks of SGLT2i use and aggressive use of the drug in patients with T2DM and its complications to alleviate symptoms are feasible.